Article
Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies†‡
Daniela Berg MD,
Ken Marek MD,
George W. Ross MD,
Werner Poewe,
Corresponding Author
Daniela Berg MD
Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany
Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases, Hoppe-Seyler-Strasse 3, 72076 Tübingen, GermanySearch for more papers by this authorKen Marek MD
Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
Search for more papers by this authorGeorge W. Ross MD
VA Pacific Islands Health Care System, Honolulu, Hawaii, USA, and Kuakini Medical Center, Honolulu, Hawaii, USA
Search for more papers by this authorWerner Poewe
Department of Neurology, University of Innsbruck, Innsbruck, Austria
Search for more papers by this authorDaniela Berg MD,
Ken Marek MD,
George W. Ross MD,
Werner Poewe,
Corresponding Author
Daniela Berg MD
Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany
Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases, Hoppe-Seyler-Strasse 3, 72076 Tübingen, GermanySearch for more papers by this authorKen Marek MD
Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
Search for more papers by this authorGeorge W. Ross MD
VA Pacific Islands Health Care System, Honolulu, Hawaii, USA, and Kuakini Medical Center, Honolulu, Hawaii, USA
Search for more papers by this authorWerner Poewe
Department of Neurology, University of Innsbruck, Innsbruck, Austria
Search for more papers by this author†
Relevant conflicts of interest/financial disclosures: Nothing to report.
‡
Full financial disclosures and author roles may be found in the online version of this article.
Abstract
It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tübinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level. © 2012 Movement Disorder Society
References
- 1
Morrish PK,
Rakshi JS,
Bailey DL,
Sawle GV,
Brooks DJ.
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
J Neurol Neurosurg Psychiatry
1998;
64:
314–319.
- 2
Fearnley JM,
Lees AJ.
Ageing and Parkinson's disease: substantia nigra regional selectivity.
Brain
1991;
114:
2283–2301.
- 3
DeKosky ST,
Marek K.
Looking backward to move forward: early detection of neurodegenerative disorders.
Science
2003;
302:
830–834.
- 4
Braak H,
Del Tredici K,
Rub U,
de Vos RA,
Jansen Steur EN,
Braak E.
Staging of brain pathology related to sporadic Parkinson's disease.
Neurobiol Aging
2003;
24:
197–211.
- 5
Halliday GM,
McCann H.
The progression of pathology in Parkinson's disease.
Ann N Y Acad Sci
2010;
1184:
188–195.
- 6
Beach TG,
Adler CH,
Lue L, et al.
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment, and motor dysfunction.
Acta Neuropathol
2009;
117:
613–634.
- 7
Lang AE,
Obeso JA.
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
Lancet Neurol
2004;
3:
309–316.
- 8
Przuntek H,
Muller T,
Riederer P.
Diagnostic staging of Parkinson's disease: conceptual aspects.
J Neural Transm
2004;
111:
201–216.
- 9
Lang AE.
A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials.
Mov Disord
2011;
26:
775–783.
- 10
Berg D.
Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection.
J Neural Transm Suppl
2006:
123–132.
- 11
Marek K,
Jennings D.
Can we image premotor Parkinson disease?
Neurology
2009;
72(
Suppl 7):
S21–S26.
- 12
Gaenslen A,
Swid I,
Liepelt-Scarfone I,
Godau J,
Berg D.
The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease.
Mov Disord
2011;
26:
653–658.
- 13
Kagan A,
Harris BR,
Winkelstein W, Jr., et al.
Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary, and biochemical characteristics.
J Chronic Dis
1974;
27:
345–364.
- 14
Abbott RD,
Ross GW,
White LR, et al.
Excessive daytime sleepiness and subsequent development of Parkinson disease.
Neurology
2005;
65:
1442–1446.
- 15
Grandinetti A,
Morens DM,
Reed D,
MacEachern D.
Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease.
Am J Epidemiol
1994;
139:
1129–1138.
- 16
Ross GW,
Abbott RD,
Petrovitch H, et al.
Association of coffee and caffeine intake with the risk of Parkinson disease.
JAMA
2000;
283:
2674–2679.
- 17
Braak H,
Del Tredici K.
Neuroanatomy and pathology of sporadic Parkinson's disease.
Adv Anat Embryol Cell Biol
2009;
201:
1–119.
- 18
Dickson DW,
Fujishiro H,
DelleDonne A, et al.
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.
Acta Neuropathol
2008;
115:
437–444.
- 19
Abbott RD,
Ross GW,
White LR, et al.
Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study.
J Neurol
2003;
250(
Suppl 3):
III30–III39.
- 20
Doty RL,
Marcus A,
Lee WW.
Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT).
Laryngoscope
1996;
106:
353–356.
- 21
Ross GW,
Petrovitch H,
Abbott RD, et al.
Association of olfactory dysfunction with risk for future Parkinson's disease.
Ann Neurol
2008;
63:
167–173.
- 22
Ross GW,
Abbott RD,
Petrovitch H, et al.
Association of olfactory dysfunction with incidental Lewy bodies.
Mov Disord
2006;
21:
2062–2067.
- 23
Abbott RD,
Petrovitch H,
White LR, et al.
Frequency of bowel movements and the future risk of Parkinson's disease.
Neurology
2001;
57:
456–462.
- 24
Teng EL.
The 3RT test: three reaction time tasks for IBM PC computers.
Behav Res Methods Instr Comput
1990;
22:
389–392.
- 25
Berg D,
Seppi K,
Liepelt I, et al.
Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly.
Mov Disord
2010;
25:
1464–1469.
- 26
Gibb WR,
Lees AJ.
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
J Neurol Neurosurg Psychiatry
1988;
51:
745–752.
- 27
Hughes AJ,
Daniel SE,
Kilford L,
Lees AJ.
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry
1992;
55:
181–184.
- 28
Berg D.
Transcranial ultrasound as a risk marker for Parkinson's disease.
Mov Disord
2009;
24(
Suppl 2):
S677–S683.
- 29
Siderowf A,
Jennings D,
Eberly S, et al.
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study.
Mov Disord
2012;
27:
406–412.
- 30
Siderowf A,
Jennings D,
Connolly J,
Doty RL,
Marek K,
Stern MB.
Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease.
Mov Disord
2007;
22:
2249–2255.
- 31
Stern MB,
Marek KL,
Friedman J, et al.
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Mov Disord
2004;
19:
916–923.
- 32
Asenbaum S,
Brucke T,
Pirker W, et al.
Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
J Nucl Med
1997;
38:
1–6.
- 33
Mozley PD,
Schneider JS,
Acton PD, et al.
Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers.
J Nucl Med
2000;
41:
584–589.
- 34
Booij J,
Habraken JB,
Bergmans P, et al.
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
J Nucl Med
1998;
39:
1879–1884.
- 35
Innis RB,
Seibyl JP,
Scanley BE, et al.
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
Proc Natl Acad Sci U S A
1993;
90:
11965–11969.
- 36
Seibyl JP,
Marek KL,
Quinlan D, et al.
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
Ann Neurol
1995;
38:
589–598.
- 37
Schwarz J,
Tatsch K,
Linke R.
Measuring the decline of dopamine transporter binding in patients with Parkinson's disease using 123I-IPT and SPECT.
Neurology
1997;
48(
Suppl 2):
A208.
- 38
Fischman AJ,
Bonab AA,
Babich JW, et al.
Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
Synapse
1998;
29:
128–141.
- 39
Marek KL,
Seibyl JP,
Zoghbi SS, et al.
[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.
Neurology
1996;
46:
231–237.
- 40
Guttman M,
Burkholder J,
Kish SJ, et al.
[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.
Neurology
1997;
48:
1578–1583.
- 41
Adams JR,
van Netten H,
Schulzer M, et al.
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Brain
2005;
128:
2777–2785.
- 42
Boeve BF.
What more can we learn from studying the REM sleep behaviour disorder-Parkinson's disease association?
J Neurol Neurosurg Psychiatry
2008;
79:
1087.
- 43
Tolosa E,
Borght TV,
Moreno E.
Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study.
Mov Disord
2007;
22:
2346–2351.
- 44
Catafau AM,
Tolosa E.
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes.
Mov Disord
2004;
19:
1175–1182.
- 45
Jennings DL,
Seibyl JP,
Oakes D,
Eberly S,
Murphy J,
Marek K.
(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis.
Arch Neurol
2004;
61:
1224–1229.
- 46
Group PS.
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Neurology
2007;
69:
1480–1490.
- 47
Group PS.
The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
Neurology
2004;
62:
330–332.
- 48
Iranzo A,
Valldeoriola F,
Lomena F, et al.
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Lancet Neurol
2011;
10:
797–805.
- 49
Postuma RB,
Gagnon JF,
Montplaisir J.
Clinical prediction of Parkinson's disease: planning for the age of neuroprotection.
J Neurol Neurosurg Psychiatry
2010;
81:
1008–1013.
- 50
Onofrj M,
Thomas A,
D'Andreamatteo G, et al.
Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.
Neurol Sci
2002;
23(
Suppl 2):
S91–S94.
- 51
Hummel T,
Konnerth CG,
Rosenheim K,
Kobal G.
Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss.
Ann Otol Rhinol Laryngol
2001;
110:
976–981.
- 52
Hautzinger M,
Bailer M,
Worall H,
Keller F.
Becks Depression Inventory (BDI).
[German]. Bern, Switzerland:
Huber;
1995.
- 53
Stiasny-Kolster K,
Mayer G,
Schafer S,
Moller JC,
Heinzel-Gutenbrunner M,
Oertel WH.
The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument.
Mov Disord
2007;
22:
2386–2393.
- 54
Oh YS,
Kim JS,
Chung SW, et al.
Color vision in Parkinson's disease and essential tremor.
Eur J Neurol
2011;
18:
577–583.
- 55
Berg D.
Is pre-motor diagnosis possible?—the European experience.
Parkinsonism Relat Disord
2012;
18(
Suppl 1):
S195–S198.
- 56
Liepelt I,
Behnke S,
Schweitzer K, et al.
Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population.
Neurobiol Aging
2011;
32:
1599–1606.
- 57
American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders,
4th ed.
Washington DC:
APA;
1994.
- 58
Marder K,
Tang MX,
Mejia H, et al.
Risk of Parkinson's disease among first-degree relatives: a community-based study.
Neurology
1996;
47:
155–160.
- 59
Parkinson Progression Marker Initiative.
The Parkinson Progression Marker Initiative (PPMI).
Prog Neurobiol
2011;
95:
629–635.
Citing Literature
